Table 1 Characteristics of the included studies.
Study name | Publication year | Country | No. of patients (Intervention /Comparator) | DDP-IV inhibitors | Other OADs | Therapy type | Study design | Follow-up period (weeks) | Timing of MAGE measurements |
|---|---|---|---|---|---|---|---|---|---|
Kim HS et al.13 | 2013 | Republic of Korea | 16/17 | Sitagliptin | Glimepiride | Add-on | Parallel | 4 | For 3 successive days at baseline and at the end of follow-up |
Xiao et al.14 | 2016 | China | 23/18 | Sitagliptin | Glimepiride | Combination | Parallel | 24 | For 72 hours, at baseline, 4, 8, 12, and 24- weeks |
Kim NH et al.9 | 2017 | Republic of Korea | 14/11 | Vildagliptin | Pioglitazone | Add-on | Parallel | 16 | For 3 consecutive days at baseline and at the end of follow-up |
Park KS et al.15 | 2017 | Republic of Korea | 16/16 | Vildagliptin | Glimepiride | Add-on | Crossover | 12 | For 3 consecutive day measurements, at baseline and at the end of follow-up |
Kim G et al.16 | 2017 | Republic of Korea | 17/17 | Vildagliptin | Glimepiride | Add-on | Parallel | 12 | For 3 consecutive day measurements, at baseline and at the end of follow-up |
Park SE et al.10 | 2017 | Republic of Korea | 24a, 21b/17 | Gemigliptin Sitagliptin | Glimepiride | Combination | Parallel | 12 | For 3 consecutive day measurements at baseline and at the end of follow-up |
Suzuki et al.17 | 2018 | Japan | 26/26 | Sitagliptin | Glibenclamide | Mono | Parallel | 2 | For 3 consecutive days at baseline and at the end of follow-up |
